Organogenesis Holdings Inc. (ORGO) Stock Score, Valuation & Financial Research
Organogenesis Holdings Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 55/100.
Quick answer for ORGO
Organogenesis Holdings Inc. currently has a Wall Street Score of 55/100. The stored market price is $1.49. Its financial score is 50/100. Its valuation score is 100/100. These figures are a research snapshot, not a buy or sell recommendation.
What Organogenesis Holdings Inc. does
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility an
ORGO financial snapshot
- Wall Street Score:
- 55/100
- Current price:
- $1.49
- Market capitalization:
- $191.7M
- Revenue:
- $513.6M
- Net income:
- $-284K
- Free cash flow:
- $-24.5M
- Cash:
- $92.1M
- Total debt:
- $70.9M
- EPS:
- 0.16
- P/E ratio:
- 9.3x
- Financial score:
- 50/100
- Valuation score:
- 100/100
- Revenue score:
- 28/100
What stands out
- Reported year-over-year revenue growth is -0.1%.
- Free cash flow is $-24.5M, showing cash burn in the current stored period.
- The balance sheet shows $92.1M of cash versus $70.9M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 50/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research ORGO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.